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Abstract 
Ca’+ fluxes were examined in HEK 293 cells stably expressing the rat or porcine calcitonin receptors (CIRs). Calcitoniu (CT) rapidly 
increased cytosolic Ca*+ ([Ca*+&) concentrations in these cells in a manner which was sustained iu the presence of extracellular Ca*+ 
([Ca*+],). In cells pretreated with CT, elevation of the [Ca*+], concentration resulted in a further increase in [Ca2+li which was 
concentration-dependent with respect to both the concentration of CT and the increment of [Ca*+],. Untrausfected cells, cells transfected 
with vector alone, and CI’R-transfected cells not treated with CT, were unresponsive to [&*‘I,. The microsomal Ca*+-ATPase inhibitor 
thapsigargin was able to mimic both the acute [Ca*+], fluxes and responsiveness to [Ca*‘], mediated by CT in these cells. The 
CT-induced responsiveness to [Ca*‘], was neither mimicked by, nor affected by, activators of the CAMP or protein kiuase C pathways. 
Treatment of cells with pertussis toxin influenced neither the primary Ca *+ fluxes in response to CT or thapsigargiu nor the 
agonist-induced [Ca*+], influx. Nifedipine failed to block responses to either CT or thapsigargiu. These results lead to the important 
conclusion that the CTR participates in receptor-activated Ca*+ 
to influx of extracellular Ca*+. 
inflow, in which depletion of intracellular Cazc pools leads secondarily 
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1. Introduction 
Calcitonin (CT) is a 32 amino acid peptide whose most 
recognised action is inhibition of osteoclastic bone resorp- 
tion [1,2]. Receptors for CT (CTR) have also been identi- 
fied in a number of other tissues including kidney [3], 
lymphocytes 141, placenta [51, hepatocytes [6] and discrete 
regions of the central nervous system [7]. Until recently the 
major focus of intracellular signalling by CT has been 
stimulation of adenylate clyclase and the CAMP-dependent 
protein kinase pathway [8,9]. However, there is growing 
evidence of CT-induced increases in cytoplasmic Ca2+ 
([Ca*+ Ii). For example, it is now clear that in the osteo- 
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clast, signalling through both CAMP and changes in [Ca2+li 
concentrations, are important in (X action [lo]. CT appar- 
ently causes either no change, or an inhibition of, adeny- 
late cyclase activity in brain tissue [ll], and there is some 
evidence that Ca*+ acts as a second messenger in this 
tissue 112,131. Likewise, in hepatocytes CT-induced adeny- 
late cyclase activity has not been shown but CT, even at 
very low concentrations, is capable of increasing [Ca*+], 
levels [14]. In LLCPK, pig kidney cells, CT can, in a cell 
cycle-dependent manner, induce either CAMP or [Ca2+li 
changes [151. The recent cloning of Cl% of pig [16], 
human [17] and rat [Ml origin identifies them as belonging 
to a new subclass of 7-transmembrane domain (7TIvID) 
G-protein coupled receptors which includes the receptors 
for parathyroid hormone, secretin, vasoactive intestinal 
polypeptide and glucagon-like peptide [19]. Expression in 
a variety of cell types has conclusively shown that the 
cloned CTR is capable of signalling through both CAMP 
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and Ca*+ second messenger systems [20,21]. CT-induced 
Ca*+ changes in CT target tissues are potentially of great 
importance since, in general, excursions of [Ca2+li are 
linked to many key cellular events [22]. 
It is now widely recognised that most cells employ 
intracellular and extracellular sources of Ca*+ in cell 
signalling. Many agonists which activate plasma mem- 
brane receptors stimulate rapid increases in [Ca2+li levels 
from intracellular stores. In the presence of extracellular 
Ca*+ ([Ca*‘],>, this induces an inflow of Ca*+ into the 
cell. This general phenomenon of agonist-induced Ca*+ 
inflow to cells has been the subject of intense study. 
Although it appears that the details differ between agonists 
and cell types, there is good evidence that agonist-induced 
emptying of [Ca2+li stores secondarily leads to opening of 
some, as yet undefined, plasma membrane Ca*+ channels 
[23]. Termed the ‘capacitative model’ [23], this was re- 
cently refined with the discovery of several soluble media- 
tors which potentially link [Ca2+li store depletion to influx 
of [Ca*+l, [24,25]. 
A recent report showed that cells transfected with the 
human CTR were rendered sensitive to changes in [Ca*+ I, 
levels, responding by increased [Ca2+liconcentration [26]. 
The CTR was therefore described by those workers as a 
‘calcium sensor’. These results were interesting in terms of 
a general understanding of the function of the CTR but 
were particularly so with respect to its function in bone-re- 
sorbing osteoclasts, which are exposed to high [Ca*+], 
concentrations [27]. Interestingly, there is an early report 
which showed that in unfractionated bone cells from em- 
bryonic rat calvariae, there was transfer of Ca*+ from the 
medium into cells which was dependent on the [Ca*+ I, 
and which was enhanced by CT [28]. It is known that the 
osteoclast is also able to sense changes in [Ca*+], and to 
respond by increasing [Ca2+li, a function believed to be 
mediated by a cell surface Ca*+ receptor [29]. It is intrigu- 
ing to speculate as to whether this receptor is itself the 
CTR or whether the function of a distinct Ca*+ receptor is 
modulated by the CTR in osteoclasts. A Ca*+ receptor was 
recently cloned from parathyroid cells [30] and like the 
CTR, was shown to belong to the 7 TMD receptor class. 
Although the osteoclast Ca*+ receptor is apparently differ- 
ent from that of the parathyroid, activation of Ca*+ recep- 
tors by Ca2+ in both osteoclasts [31] and parathyroid cells 
[30,32] results in release of Ca *+ from intracellular storage 
organelles, which in turn activates capacitative influx of 
[Ca’+],. 
We were interested to enquire whether the CTR sensi- 
tises cells to Ca*+ by itself acting as a Ca*+ receptor or 
whether its stimulation of extracellular Ca*+ inflow occurs 
secondarily to intracellular signalling. We have used HEK 
293 cells, in which there is no evidence for the presence of 
a Ca*+ receptor, stably transfected with cloned rat or 
porcine CTR and compared CT-mediated Ca*+ inflow 
with Ca*+ inflow stimulated by thapsigargin. The results 
suggest that the rat and porcine CTR in HEK 293 cells 
mediate Ca*+ influx in a manner consistent with capacita- 
tive Ca*+ inflow described for several other receptor 
systems. 
2. Materials and methods 
2.1. Hormones and chemicals 
The porcine CTR (pCTR) cDNA clone 3J8-14-Fl was a 
gift from Dr H. Lin (Boston, MA, USA). Synthetic salmon 
calcitonin (sCT) was from Bachem (Torrance, CA, USA). 
8-bromoadenosine 3’,5’-cyclic monophosphate (&bromo 
CAMP), thapsigargin and phorbol 12-myristate 13-acetate 
(PMA) were purchased from the Sigma Chemical Co. (St. 
Louis, MO). All other chemicals were of reagent grade and 
obtained from standard suppliers. 
2.2. Cell culture 
Cell lines used in these studies were human embryonic 
kidney (HEK 293) cells stably transfected with the rat 
CTR Cla and Clb isoforms [18], the porcine CTR [16] or 
the plasmid vector pCDNA-l,, (Invitrogen, San Diego, 
USA). The preparation and characterisation of these stably 
transfected cell lines is described elsewhere [33]. Briefly, 
cells were transfected by the calcium phosphate method 
and 48 h after transfection G418 was added to the medium 
and selection maintained for 2 weeks. G418 resistant cells 
were subcloned by two rounds of limiting dilution. Cloned 
cells were screened for CTR expression by measurement 
of 1251-sCT binding. Receptor numbers per cell in the cells 
selected and used for the studies herein, were approxi- 
mately: Cla cells, 5 . 10’; Clb cells, 6. 106; porcine 
CTR-expressing cells, 9 * 106. Cells were maintained at 
37°C in a humidified atmosphere with 5% CO, in air, in 
complete Dulbecco’s Modified Eagle’s medium (DME, 
Gibco, Grand Island, NY) containing 5% fetal bovine 
serum (FBS) (Cytosystems, NSW, Australia), 80 mg/l 
gentamicin (Delta West, WA, Australia), 1 mg/l minocy- 
cline (Sigma, St. Louis, MO), 15 mM Hepes (Gibco) and 
200 pg/ml G418. 
2.3. Intracellular calcium measurement 
Intracellular Ca*+ measurements were made in cells in 
suspension. Cells grown in 75 cm* flasks were changed to 
phenol red-free DME containing 10% FBS approximately 
2 h before experiments. For experiments, the cells were 
treated briefly with trypsin/EDTA, centrifuged and resus- 
pended in 10 ml assay medium (phenol red-free DME 
containing 0.1% (w/v) Pentex lipid-free BSA (Miles Sci- 
entific, Naperville, IL) and containing u 1.8 mM Ca*+). 
The cells in suspension were loaded with fura- (Molecu- 
lar Probes, Eugene, OR) by incubating with 2 PM of the 
acetoxymethyl ester (dissolved in dimethyl sulfoxide) for 
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30 min at 37”C/5% CO, as described [34]. The cells were 
then centrifuged at approx. 500 X g for 5 min and washed 
once with 10 ml assay medium. The supematant was 
removed and the pellet resuspended in medium at a con- 
centration of approximately lo6 cells/ml. Fluorescence 
(emission 505 nm) was mleasured from cells excited at 340 
and 380 nm using a Spex Fluorolog 2 spectrofluorimeter. 
Cells were kept in suspension by gentle stirring and were 
maintained at 37°C during the course of experiments. 
Calibration and calculation of intracellular calcium concen- 
tration ([Ca” I,) were performed as previously described 
[351. 
3. Results 
3.1. Effect of calcitonin a.nd [Ca’ ‘1, on [Ca’ ‘Ii 
Intracellular calcium measurements were made in sus- 
pensions of fura-2-loaded cells. Most experiments were 
carried out using cells stably expressing the Clb isoform 
of the rat CIR because the high receptor number in these 
cells resulted in consistent and easily measurable re- 
sponses. Salmon CT rapidly increased [Ca”], in these 
cells in a dose-dependent manner, and [Ca”], was sus- 
tained above the basal level when cells were incubated in 
medium containing Ca2+ (Fig. 1A). In addition, in cells 
pretreated with sCT, subsequent elevation of the [Ca2+], 
concentration resulted in a further increase in [Ca2+li (Fig. 
1A). These events were also observed in HEK 293 cells 
transiently transfected with the Clb CTR (not shown) or 
stably transfected with the Cla isoform of the rat CTR (not 
shown) or the porcine CTR (Fig. 1D). 
Increases in [Ca2+], only influenced [Ca2’li when 
CTR-expressing HEK 293 cells were first exposed to CT 
(compare Fig. 6A and B).. Non transfected HEK 293 cells, 
or cells transfected with the pCDNA-l,, vector only, 
were unresponsive to CT or to elevation of [Ca2+], con- 
centration, regardless of the order of addition (see Fig. 5). 
We considered it relevant to simulate physiological 
conditions so that in the present study the cells were 
suspended in phenol red-free DME with an ambient [Ca2+], 
of 1.8 mM. However, in order to compare our results with 
those achieved in several other systems [26,36,37], some 
cell suspensions were treated with 4 mM EGTA before 
testing the effects of SC?’ and [Ca2’],. In the presence of 
chelated [Ca2+],, sCT again induced a rapid increase in 
[Ca2+li but the sustained phase of this response was absent 
(Fig. 1B). This result is consistent with CT induction of 
Ca2+ release from intracellular stores by an IP,-mediated 
process, for which there is evidence in the case of the 
porcine CTR [20,21], whlie the sustained phase appears to 
be due to influx of extracellular Ca2+. Following sCT 
pretreatment in Ca 2+-deplleted medium, step-wise increases 
in the [Ca2+], resulted in corresponding increases in 
[Ca2+li (Fig. 1B) which was not seen when the cells were 
not first exposed to sCT (Fig. 1C). 
(-9 
0 300 
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Fig. 1. Effect of salmon CT and [Ca’+ 1, upon [Ca*’ Ii of CTR-bearing 
cells. [Ca*+ Ii concentration was measured in suspensions of fura-Zloaded 
HEK 293 cells stably expressing the Clb isoform of the rat CTR (A-C) 
or the porcine CTR (D). Cells were treated with sCT (S) at 10W7 M (A) 
or lOma M (B,D), and the [Ca*’ 1, concentration, C, was raised by the 
amount indicated (in mM). For example, Cl indicates an increment of 1 
mM in [Ca*+ I,, CL.5 by 2.5 mM and so on. In (B) and (C), cells were 
first made 4 mM with respect to EGTA (E). Tracings are representative 
of at least 3 separate experiments. 
The magnitude of the CT-induced Ca2+ influx was 
examined in Clb-expressing cells with respect to the con- 
centration of sCT used for pretreatment, and the concentra- 
tion of [Ca2’],. The magnitude of the change in [Ca2+li in 
response to an elevation in [Ca2’], of 5 mM (from a basal 
of N 1.8 mM) was dependent upon the concentration of 
sCT over the range 1 nM to 1 PM. The results of two 
separate experiments are shown in Fig. 2, each of which 
exhibited threshold responses with ~2 nM sCT. After 
exposure to 10 nM sCT, an increase in [Ca2’], of as little 
as 1 mM resulted in increased [Ca2+li. Fig. 3 shows a 
representation of four experiments. [Ca2+], concentrations 
up to 25 mM were examined because osteoclasts are 
reportedly exposed to calcium concentrations as high as 26 
mM during bone resorption 1271. The maximal response in 
HEK 293 cells, however, was to an increase in [Ca2+], of 
between 5 and 10 mM. 
3.2. Comparison of CT- and thapsigargin-stimulated Ca2 ’ 
entry 
Thapsigargin is an inhibitor of microsomal Ca2+-ATPase 
activity and as such has been extremely useful in unravel- 
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Fig. 2. Responses to increases in [Ca’+ 1, of cells expressing the Clb rat 
ClR after treatment with different concentrations of salmon CT. Suspen- 
sions of fura-Zloaded HEK 293 cells stably expressing the Clb ClR 
were treated with the indicated concentrations of sCT prior to elevation 
by 5 mM of the [Ca’+ 1, concentration. Basal [Ca*+ 1, concentration was 
- 1.8 mM. Results of two separate representative experiments are shown 
(closed and open circles) and are expressed as the increase of [Ca*+ Ii 
concentration due to the increment in [Ca*+ 1,. Points are means of 
duplicate determinations. 
2.5 10 25 
A[Ca2+]e (mM) 
Fig. 3. Response to different elevations of [Ca*+ 1, concentration in 
salmon CT-treated HEK 293 cells expressing the rat Clb CIR. Suspen- 
sions of fura-Zloaded cells were treated with 1O-8 M sCT prior to 
elevation of the [Ca*+ 1, by the increments indicated. Basal [Ca*’ 1, 
concentration was - 1.8 mM. Results of a representative of four separate 
experiments are shown and are expressed as the increase of [CL?+ Ii 
concentration due to the increase in [Ca*+ 1,. Points are means of 
duplicate determinations. 
ling the mechanisms of capacitative Ca*+ entry. It is able 
to mimic the action of many but not all agonists in 
inducing Ca* + entry by acting directly to discharge the 
agonist-sensitive intracellular Ca*+ pool [37]. We therefore 
compared the action of thapsigargin with that of CT in 
HEK 293 cells expressing the Clb rat CTR. Like sCT, 
thapsigargin also induced a rapid increase in [Ca2+li which 
was sustained in the presence of extracellular Ca*+ (com- 
pare Fig. 4A and C) but was transient in cell suspensions 
treated with thapsigargin in the presence of EGTA (Fig. 
4E). In cells treated with thapsigargin there was also a 
further increase in [Ca2+li in response to an incremental 
increase in [Ca*‘], (Fig. 4C, F). Since both CT and 
thapsigargin sensitise cells to extracellular calcium, these 
results suggest that CT and thapsigargin may act in a 
similar manner to induce Ca*+ inflow by a capacitative 
entry mechanism. 
Thapsigargin-induced Ca*’ inflow was not dependent 
upon the presence of the CTR. HEK 293 cells stably 
transfected with pCDNA-l,,, alone were also rendered 
sensitive to [Ca*+], by thapsigargin (Fig. 5B), although 
not CT (Fig. 5C), treatment. Fig. 5A shows that vector- 
transfected cells did not respond to [Ca*+], without thapsi- 
gargin treatment. 
3.3. Mechanism by which calcitonin mediates [Ca2 ‘1, 
effects 
Experiments were designed to examine the mechanism 
of CT-induced Ca *+ influx in HEK 293 cells transfected 
with the rat Clb ClR isoform. Cells were treated for short 
(approx. 1 min) or long (up to 30 min) periods with 
agonists of the CAMP pathway, Sbromo CAMP or 
forskolin, or the phorbol ester, phorbol 1Zmyristate 13 
acetate (PMA) which activates PKC. Neither short (Fig. 
6A, D) nor long (not shown) treatment with these agents 
alone resulted in responsiveness to changes in [Ca*‘], in 
cells not treated with CT. Moreover, none of the treat- 
ments significantly modified &T-induced [Ca*+ 1, re- 
sponses to increased [Ca2+le. The particular examples 
shown are PMA (Fig. 6C) or 8-bromo CAMP treatment, 
the latter added before [Ca*+ 1, elevation (Fig. 6D), before 
sCT addition (Fig. 6E) or after sCT and before [Ca2+le 
elevation (Fig. 6F). The small (approx. 2-fold) difference 
in [Ca*+ Ii levels within this experiment were difficult to 
avoid in experiments run over several hours. However, 
from results of several such experiments it was concluded 
that qualitatively neither CAMP pathways, nor those in- 
volving activated PKC, were responsible for CT-mediated 
Ca*+ inflow. 
In order to determine the contribution of G proteins in 
CTR-mediated Ca*+ inflow, it was of interest to determine 
whether this mechanism is sensitive to pertussis toxin. This 
was found not to be the case in HEK 293 cells expressing 
the Clb CTR receptor treated for 16 h with pertussis toxin. 
Both CT-stimulated [Ca*+l,, and Ca*+ influx due to sub- 
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sequent elevation of [Ca?+le, were essentially identical 
between control cells (Fig. 4A) and cells pretreated with 
pertussis toxin (Fig. 4B). The same result was obtained in 
cells pretreated for 30 min (results not shown). In addition, 
results qualitatively similar to control were obtained with 
thapsigargin in cells pretreated with pertussis toxin for 30 
min (not shown) or 16 .h (Fig. 4D, F>. Activity of the 
pertussis toxin preparation used was confirmed indepen- 
dently (not shown). 
The means by which <:a’+ obtains entry in agonist-in- 
duced Ca2+ inflow is not clear, but the ineffectiveness of 
most inhibitors of voltage-operated calcium channels sug- 
gests that these two mechanisms are distinct. For example, 
receptor-activated Ca2+ entry in hepatocytes is reportedly 
inhibitable only by high concentrations (100 PM) of the 
Ca2+ channel blockers vlerapamil and nifedipine [38], at 
which concentrations their effects are likely to be nonspe- 
cific [39]. These agents inhibit Gtype voltage-operated 
CaZf channels at concentrations in the range 100 nM [38]. 
We tested nifedipine at a concentration of 10 PM for 
blockade of CT or thapsigargin-induced Ca2+ inflow and 
in neither case was this agent effective whether added first 
or before [Ca”], elevation (not shown). Since these re- 
sults are consistent with those in other systems, it therefore 
appears that in the case of CTR activated calcium influx 
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Fig. 4. [Ca*+ Ii responses to thapsigargin or sCT in control cells (A,C,E) 
or cells pretreated with pertussis toxin overnight (B,D,F). Suspensions of 
fura-2-loaded cells expressing the. Clb rat C’lR were examined for Ca’+ 
fluxes in response to sCT (S) at lo-’ M or thapsigargin (T) at 2 PM. 
Responses to subsequent elevation of [Ca*+ 1, concentration, C, of 12.5 
mM (from a basal of u 1.8 mM) were determined. Responses to thapsi- 
gargin and [Ca*+ 1, were also determined in cells first made 4 mM with 
respect to EGTA (E). Results are representative of three separate experi- 
ments. 
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Fig. 5. [Ca*+ Ii responses to thapsigargin or sC’I in HEK 293 cells stably 
transfected wtth pCDNA-l,, vector alone. Suspensions of fura-Zloaded 
cells stably transfected with pCDNA-l,so were examined for Cr*+ 
fluxes in response to vehicle (V), thapsigargin (T) at 2 PM, sCT (S) at 
lo-’ M, Ca*+ (C) at 10 mM, or ionomycin (I) at 10m6 M (added to 
confirm the responsiveness of the system). (A), (B) and (C) are represen- 
tative tracings using aliquots of cells from the same batch. 
also, the relevant calcium channels are distinct from volt- 
age-operated channels. 
4. Discussion 
We consider that the most likely interpretation of the 
above results is that the CTR allows cells to respond to 
increases in [Ca2+], levels secondarily to CT-induced 
intracellular Ca2 + fluxes rather than by functioning as a 
Ca2+ sensor per se. This conclusion is based on the 
similarity between the CT-mediated Ca2+ influx and the 
Ca2+ influx induced by other agents, for example EGF or 
vasopressin [36]. Like HEK 293 cells expressing the rat 
and porcine CTR, responses to extracellular Ca2+ in these 
other systems also depend on the presence of the receptor 
ligand. Ligand binding is believed to stimulate emptying of 
intracellular Cazf pools, an action mimicked by thapsigar- 
gin treatment, and this reagent enables HEK 293 cells to 
respond to [Ca*‘], in a very similar fashion to CT treat- 
ment. 
The results of our mechanistic studies were analogous 
to previous reports [40,41] which indicated that activation 
of PKC was not involved in Ca*+ uptake in hepatocytes 
induced by vasopressin or angiotensin II. Although these 
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Fig. 6. Effect of activators of protein kinase A and C upon [Ca*+ Ii fluxes 
in Clb CTR-expressing cells. [Ca” Ii concentrations were measured in 
suspensions of fura-Z-loaded cells in response to sCT (S) at low7 M, and 
an increase in [Ca*+ 1, (C) of 25 mM. Basal [Ca’+ I, was * 1.8 mM. 
Responses were determined in control cells (A, B) or cells briefly treated 
with PMA (P) at 10m6 M (C) or 8-Bromo CAMP (8Br) at lOA M 
(D-F). These tracings of [Ca*+ Ii vs. time are representative of three 
qualitatively similar experiments. 
agonists do not affect CAMP levels in hepatocytes, CAMP 
is a potentially important mediator of agonist-activated 
Cazf inflow since the action of glucagon to synergistically 
increase Ca2 + inflow to hepatocytes caused by angiotensin 
II or vasopressin is CAMP- dependent [21]. Consistent with 
the lack of effect of CAMP agonists in the present study, 
Stroop et al. [26] showed that addition of 8-bromo CAMP 
or forskolin to CTR-naive BHK cells did not result in 
Ca2+ influx in response to increased [Ca*+],. However, 
these workers did not report on the same experiment ,in 
cells expressing the CTR. 
There is mounting evidence that heterotrimeric GTP 
binding regulatory proteins (G-proteins) have a role in 
agonist-induced Ca2+ inflow in several systems [391. It 
appears that more than one G-protein is involved and that 
there is heterogeneity between different agonists and cell 
types. The work of Berven et al. [36], for example, sug- 
gests that vasopressin-stimulated Ca2+ inflow in the hepa- 
tocyte requires a G-protein which is relatively insensitive 
to pertussis toxin, while EGF-stimulated Ca2+ inflow in 
the same cell is completely inhibited by pertussis toxin, 
suggesting involvement of a rapidly ADP-ribosylated G- 
protein. The recent report of Bird and Putney [36] indicates 
involvement in mouse lacrimal acinar cells of a G-protein 
whose activation depends on GTP hydrolysis, rather than 
GTP binding. Although pertussis toxin was without effect 
in the present work, it remains possible that G-proteins are 
involved in the Ca2+ entry mediated by Cl? and thapsigar- 
gin in HEK 293 cells, but the results show that such a 
protein(s) is not a substrate for pertussis toxin ADP ribo- 
sylation. 
The hypothesis of Stroop et al. [26] was that the human 
CTR is a calcium sensor, since its expression enabled cells 
to ‘sense’ changes in [Ca2+],. If the CTR were in fact 
acting as a Ca2+ receptor, cells would require the presence 
of the CTR but not necessarily ligand binding or sig- 
nalling. This was found to be the case for the human CTR 
receptor in T47D cells and for some clonal BHK cell lines 
expressing the human CTR receptor [26], however re- 
sponses to [Ca2+], in human CTR-transfected 9B13 cells 
required preexposure to CT [26]. Likewise, we found that 
responsiveness to changes in [Ca2+], by HEK 293 cells 
expressing the rat or porcine CTRs was totally CT depen- 
dent. The explanation for the ability of some human 
CTR-expressing cells to ‘sense’ extracellular Ca2+ in- 
creases, in the absence of CT 1261 is not known. It is 
possible that high concentrations of receptor in transfected 
cells sometimes allows a percentage of receptors to couple 
agonist-independently to phospholipase C (PLC) activa- 
tion. Agonist-free coupling could also occur in T47D cells, 
or alternatively these cells may have some other Ca*+ 
sensing mechanism. 
If the CTR is a separate entity from the Ca2+ receptor 
on cells such as osteoclasts, it will be important to deter- 
mine the role of each in directing intracellular events in the 
face of [Ca2+], changes. The CTR is clearly capable of 
mediating [Ca2+li increases in response to both CT and 
[Ca2+],. Therefore it will also be important to study the 
consequences of receptor-mediated intracellular Ca2+ 
fluxes in CTR-bearing cells which do not appear to re- 
spond to CT with a CAMP increase, and also to dissect out 
the roles of these second messengers in cells in which both 
pathways are elicited. For example, it has been known for 
many years that CT can potently inhibit the growth of 
CTR-bearing cells, an action believed to be mediated by 
the specific activation of the type II isoenzyme of the 
CAMP-dependent protein kinase [9]. Recently, several 
points of intersection for CAMP inhibition of growth fac- 
tor-stimulated proliferation pathways have been identified 
[42,43]. However, recent reports also support a role for 
Ca2+-activated pathways in growth modulation; depletion 
of intracellular Ca2+ stores by thapsigargin was implicated 
in inhibition of cell growth [44] and mitogenesis by throm- 
bin and bradykinin appeared to involve Gq-mediated in- 
creases in [Ca2+li [45]. We have found that CT treatment 
of mouse marrow culture decreases the production of both 
mononuclear and multinuclear osteoclast-like cells 
(Ikegame and Findlay, unpublished data). In addition, in 
mouse bone marrow culture, CT has been found to inhibit 
the fusion process leading to multinucleate osteoclast for- 
mation, while not affecting formation of the tartrate acid- 
resistant phosphatase-positive mononuclear precursors [46]. 
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It would therefore be of interest to determine whether the 
interplay between CT and [Ca2’], is important not only in 
the acute function of actively resorbing osteoclasts in bone, 
as has been recognised [lo], but also in the progression of 
precursors to multinucleated osteoclasts. 
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